提高癌症免疫治疗临床成功率的方法框架。 - Suppr

Suppr

超能文献

A methodological framework to enhance the clinical success of cancer immunotherapy.

作者信息

Hoos Axel, Britten Cedrik M, Huber Christoph, O'Donnell-Tormey Jill

出版信息

Nat Biotechnol. 2011 Oct 13;29(10):867-70. doi: 10.1038/nbt.2000.

DOI:10.1038/nbt.2000

PMID:21997622

Abstract

摘要

相似文献

A methodological framework to enhance the clinical success of cancer immunotherapy.

Nat Biotechnol. 2011 Oct 13;29(10):867-70. doi: 10.1038/nbt.2000.

Towards In Silico Prediction of the Immune-Checkpoint Blockade Response.

Trends Pharmacol Sci. 2017 Dec;38(12):1041-1051. doi: 10.1016/j.tips.2017.10.002. Epub 2017 Oct 28.

Cancer immunotherapy shows promise in multiple tumor types.

Nat Med. 2012 Jul 6;18(7):993. doi: 10.1038/nm0712-993.

Biomarkers associated with checkpoint inhibitors.

Ann Oncol. 2016 Jul;27(7):1199-206. doi: 10.1093/annonc/mdw181. Epub 2016 Apr 27.

Breakthrough of the year 2013. Cancer immunotherapy.

Science. 2013 Dec 20;342(6165):1432-3. doi: 10.1126/science.342.6165.1432.

Genetic basis for response to cancer immunotherapy.

Lancet Oncol. 2017 Sep;18(9):e521. doi: 10.1016/S1470-2045(17)30627-7. Epub 2017 Aug 17.

Part II: Checkpoint inhibitors in cancer therapy.

Immunotherapy. 2016 Jun;8(7):761-2. doi: 10.2217/imt-2014-0051.

Predicting immunotherapy response through genomics.

Curr Opin Genet Dev. 2021 Feb;66:1-9. doi: 10.1016/j.gde.2020.11.004. Epub 2020 Dec 8.

Cancer Immunotherapy Researchers Focus on Refining Checkpoint Blockade Therapies.

JAMA. 2015 Nov 24;314(20):2117-9. doi: 10.1001/jama.2015.10795.

Biomarkers of hyperprogression and pseudoprogression with immune checkpoint inhibitor therapy.

Future Oncol. 2019 Aug;15(22):2645-2656. doi: 10.2217/fon-2019-0183. Epub 2019 Jul 12.

引用本文的文献

Enhancing Cancer Vaccine Efficacy: siRNA-Based Modulation of Immune Suppressive Factors in Dendritic Cells.

Methods Mol Biol. 2025;2965:259-273. doi: 10.1007/978-1-0716-4742-4_12.

Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab.

Front Oncol. 2021 Mar 9;11:624780. doi: 10.3389/fonc.2021.624780. eCollection 2021.

Phase I Clinical Trial Using Autologous Ex Vivo Expanded NK Cells and Cytotoxic T Lymphocytes for Cancer Treatment in Vietnam.

Int J Mol Sci. 2019 Jun 28;20(13):3166. doi: 10.3390/ijms20133166.

Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers.

Clin Cancer Res. 2018 Aug 15;24(16):3845-3856. doi: 10.1158/1078-0432.CCR-17-2707. Epub 2018 Jul 17.

Do immune checkpoint inhibitors need new studies methodology?

J Thorac Dis. 2018 May;10(Suppl 13):S1564-S1580. doi: 10.21037/jtd.2018.01.131.

Interim Futility Monitoring Assessing Immune Therapies With a Potentially Delayed Treatment Effect.

J Clin Oncol. 2018 Aug 10;36(23):2444-2449. doi: 10.1200/JCO.2018.77.7144. Epub 2018 Jun 27.

Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity.

Clin Cancer Res. 2017 Sep 1;23(17):4959-4969. doi: 10.1158/1078-0432.CCR-16-3065.

End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma.

Future Oncol. 2017 Jun;13(13):1181-1193. doi: 10.2217/fon-2016-0504. Epub 2017 Apr 11.

Diversification of Antitumour Immunity in a Patient with Metastatic Melanoma Treated with Ipilimumab and an IDO-Silenced Dendritic Cell Vaccine.

Case Rep Med. 2016;2016:9639585. doi: 10.1155/2016/9639585. Epub 2016 Jul 18.

Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations.

Nat Rev Drug Discov. 2016 Apr;15(4):235-47. doi: 10.1038/nrd.2015.35. Epub 2016 Mar 11.

本文引用的文献

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

N Engl J Med. 2011 Jun 30;364(26):2517-26. doi: 10.1056/NEJMoa1104621. Epub 2011 Jun 5.

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.

Science. 2011 Mar 25;331(6024):1565-70. doi: 10.1126/science.1203486.

Immune parameters affecting the efficacy of chemotherapeutic regimens.

Nat Rev Clin Oncol. 2011 Mar;8(3):151-60. doi: 10.1038/nrclinonc.2010.223.

Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.

Semin Oncol. 2010 Oct;37(5):533-46. doi: 10.1053/j.seminoncol.2010.09.015.

Improved endpoints for cancer immunotherapy trials.

J Natl Cancer Inst. 2010 Sep 22;102(18):1388-97. doi: 10.1093/jnci/djq310. Epub 2010 Sep 8.

Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

N Engl J Med. 2010 Jul 29;363(5):411-22. doi: 10.1056/NEJMoa1001294.

Improved survival with ipilimumab in patients with metastatic melanoma.

N Engl J Med. 2010 Aug 19;363(8):711-23. doi: 10.1056/NEJMoa1003466. Epub 2010 Jun 5.

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.

Clin Cancer Res. 2009 Dec 1;15(23):7412-20. doi: 10.1158/1078-0432.CCR-09-1624. Epub 2009 Nov 24.

"MIATA"-minimal information about T cell assays.

Immunity. 2009 Oct 16;31(4):527-8. doi: 10.1016/j.immuni.2009.09.007.

Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium.

Cancer Immunol Immunother. 2009 Oct;58(10):1701-13. doi: 10.1007/s00262-009-0681-z. Epub 2009 Mar 4.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

A methodological framework to enhance the clinical success of cancer immunotherapy.

Nat Biotechnol. 2011 Oct 13;29(10):867-70. doi: 10.1038/nbt.2000.

Towards In Silico Prediction of the Immune-Checkpoint Blockade Response.

Trends Pharmacol Sci. 2017 Dec;38(12):1041-1051. doi: 10.1016/j.tips.2017.10.002. Epub 2017 Oct 28.

Cancer immunotherapy shows promise in multiple tumor types.

Nat Med. 2012 Jul 6;18(7):993. doi: 10.1038/nm0712-993.

Biomarkers associated with checkpoint inhibitors.

Ann Oncol. 2016 Jul;27(7):1199-206. doi: 10.1093/annonc/mdw181. Epub 2016 Apr 27.

Breakthrough of the year 2013. Cancer immunotherapy.

Science. 2013 Dec 20;342(6165):1432-3. doi: 10.1126/science.342.6165.1432.

Genetic basis for response to cancer immunotherapy.

Lancet Oncol. 2017 Sep;18(9):e521. doi: 10.1016/S1470-2045(17)30627-7. Epub 2017 Aug 17.

Part II: Checkpoint inhibitors in cancer therapy.

Immunotherapy. 2016 Jun;8(7):761-2. doi: 10.2217/imt-2014-0051.

Predicting immunotherapy response through genomics.

Curr Opin Genet Dev. 2021 Feb;66:1-9. doi: 10.1016/j.gde.2020.11.004. Epub 2020 Dec 8.

Cancer Immunotherapy Researchers Focus on Refining Checkpoint Blockade Therapies.

JAMA. 2015 Nov 24;314(20):2117-9. doi: 10.1001/jama.2015.10795.

Biomarkers of hyperprogression and pseudoprogression with immune checkpoint inhibitor therapy.

Future Oncol. 2019 Aug;15(22):2645-2656. doi: 10.2217/fon-2019-0183. Epub 2019 Jul 12.

引用本文的文献

Enhancing Cancer Vaccine Efficacy: siRNA-Based Modulation of Immune Suppressive Factors in Dendritic Cells.

Methods Mol Biol. 2025;2965:259-273. doi: 10.1007/978-1-0716-4742-4_12.

Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab.

Front Oncol. 2021 Mar 9;11:624780. doi: 10.3389/fonc.2021.624780. eCollection 2021.

Phase I Clinical Trial Using Autologous Ex Vivo Expanded NK Cells and Cytotoxic T Lymphocytes for Cancer Treatment in Vietnam.

Int J Mol Sci. 2019 Jun 28;20(13):3166. doi: 10.3390/ijms20133166.

Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers.

Clin Cancer Res. 2018 Aug 15;24(16):3845-3856. doi: 10.1158/1078-0432.CCR-17-2707. Epub 2018 Jul 17.

Do immune checkpoint inhibitors need new studies methodology?

J Thorac Dis. 2018 May;10(Suppl 13):S1564-S1580. doi: 10.21037/jtd.2018.01.131.

Interim Futility Monitoring Assessing Immune Therapies With a Potentially Delayed Treatment Effect.

J Clin Oncol. 2018 Aug 10;36(23):2444-2449. doi: 10.1200/JCO.2018.77.7144. Epub 2018 Jun 27.

Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity.

Clin Cancer Res. 2017 Sep 1;23(17):4959-4969. doi: 10.1158/1078-0432.CCR-16-3065.

End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma.

Future Oncol. 2017 Jun;13(13):1181-1193. doi: 10.2217/fon-2016-0504. Epub 2017 Apr 11.

Diversification of Antitumour Immunity in a Patient with Metastatic Melanoma Treated with Ipilimumab and an IDO-Silenced Dendritic Cell Vaccine.

Case Rep Med. 2016;2016:9639585. doi: 10.1155/2016/9639585. Epub 2016 Jul 18.

Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations.

Nat Rev Drug Discov. 2016 Apr;15(4):235-47. doi: 10.1038/nrd.2015.35. Epub 2016 Mar 11.

本文引用的文献

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

N Engl J Med. 2011 Jun 30;364(26):2517-26. doi: 10.1056/NEJMoa1104621. Epub 2011 Jun 5.

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.

Science. 2011 Mar 25;331(6024):1565-70. doi: 10.1126/science.1203486.

Immune parameters affecting the efficacy of chemotherapeutic regimens.

Nat Rev Clin Oncol. 2011 Mar;8(3):151-60. doi: 10.1038/nrclinonc.2010.223.

Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.

Semin Oncol. 2010 Oct;37(5):533-46. doi: 10.1053/j.seminoncol.2010.09.015.

Improved endpoints for cancer immunotherapy trials.

J Natl Cancer Inst. 2010 Sep 22;102(18):1388-97. doi: 10.1093/jnci/djq310. Epub 2010 Sep 8.

Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

N Engl J Med. 2010 Jul 29;363(5):411-22. doi: 10.1056/NEJMoa1001294.

Improved survival with ipilimumab in patients with metastatic melanoma.

N Engl J Med. 2010 Aug 19;363(8):711-23. doi: 10.1056/NEJMoa1003466. Epub 2010 Jun 5.

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.

Clin Cancer Res. 2009 Dec 1;15(23):7412-20. doi: 10.1158/1078-0432.CCR-09-1624. Epub 2009 Nov 24.

"MIATA"-minimal information about T cell assays.

Immunity. 2009 Oct 16;31(4):527-8. doi: 10.1016/j.immuni.2009.09.007.

Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium.

Cancer Immunol Immunother. 2009 Oct;58(10):1701-13. doi: 10.1007/s00262-009-0681-z. Epub 2009 Mar 4.